PharmaEssentia (6446 TW) stock market data APIs
NT$554.2256
-8.13(-1.5%)
as of July 1, 2025
Try our APIs with
free plan!
PharmaEssentia Financial Data Overview
Price chart is built with
Anychart
PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia. In addition, it focuses on the drug research and development programs in the areas of hematology, infectious disease, and oncology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.
Prev. Close
554.2256
Open
546.0982
High
558.4885
Low
536.0538
52 wk Range
440-796
Market Cap
182 667 M
P/E Ratio
47.0437
Shares Outstanding
333 M
Revenue
11 339 M
EPS
3.8
Beta
-0.104
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get PharmaEssentia data using free add-ons & libraries
Get PharmaEssentia Fundamental Data
PharmaEssentia Fundamental data includes:
- Net Revenue: 11 339 M
- EBITDA: 2 938 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-11
- EPS/Forecast: 3
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
PharmaEssentia News
New
PharmaEssentia Announces Presentations at EHA 2025 Highlighting Clinical Advances in Myeloproliferative Neoplasms
Selected plenary presentation highlights positive Phase 3 SURPASS-ET clinical trial results of ropeginterferon alfa-2b-njft for the treatment of essential thrombocythemia (ET) Additional oral present...
PharmaEssentia to Present Phase 3 SURPASS-ET Data in Oral Session at 2025 ASCO Annual Meeting
Presentation to include positive clinical results from the Phase 3 SURPASS-ET clinical trial of ropeginterferon alfa-2b-njft for the treatment of essential thrombocythemia (ET) BURLINGTON, Mass., May...
PharmaEssentia Highlights Availability of BESREMi® (ropeginterferon alfa-2b-njft) for Patients Affected by Pegasys® (peginterferon alfa-2a) Drug Shortage
BESREMi® recognized by National Comprehensive Cancer Network® (NCCN®) as an appropriate substitute for Pegasys® in the face of ongoing supply limitations BURLINGTON, Mass., March 04, 2025--(BUSIN...
CORRECTING and REPLACING PharmaEssentia Announces Positive Topline Phase 3 Data from SURPASS-ET Study Evaluating Ropeginterferon Alfa-2b-njft (P1101) for Essential Thrombocythemia
SURPASS-ET trial achieved its primary endpoint, demonstrating a durable response in 42.9% of participants in the P1101 group versus 6.0% in the comparator group (p=0.0001) Data support our plan to su...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
